Zealand initiates Phase IIa clinical trial with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zealand initiates Phase IIa clinical trial with dasiglucagon in a dual-hormone artificial pancreas system from Beta Bionics

Press Release - No. 7 / 2016  

  • An automated delivery system with both insulin and glucagon holds potential to become a paradigm shift in the treatment of type 1 diabetes  
  • In December, Zealand initiated two Phase IIa trials, to test dasiglucagon's potential in a dual-hormone artificial pancreas system  
  • Results from both trials are expected in H1 2017

Zealand Pharma (Zealand) today announced that it has dosed the first patients in its Phase IIa clinical trial with dasiglucagon [1] in a dual-hormone artificial (or bionic) pancreas system from Beta Bionics. Dasiglucagon is a Zealand-invented glucagon analogue with a unique stability profile in liquid formulation. The multiple-dose version of dasiglucagon is intended for use in a dual-hormone artificial pancreas system to better control hypoglycaemia and, potentially, hereby provide insulin treated diabetes patients with options for easier and more effective management of their disease.

The Phase IIa trial is the fourth Phase II trial initiated by Zealand this year, demonstrating the significant progress in Zealand's pipeline of proprietary product candidates.

People with type 1 diabetes depends on a complex daily insulin regimen to control their blood glucose. They must regularly track and adjust their blood sugar levels to reduce the acute and chronic risks associated with hypo- and hyperglycaemia. A dual-hormone artificial (or bionic) pancreas system, which automatically delivers insulin and glucagon, aims to mimic the function of a healthy pancreas [2] . 

Steven J. Russell, MD, Massachusetts General Hospital Diabetes Center in Boston, MA, USA, and Principal Investigator: " Our previous studies have shown that a dual-hormonal bionic pancreas can provide very effective management of glycemia in people with type 1 diabetes. All of our previous studies have used glucagon that have very limited stability, so the glucagon pump had to be refilled daily. More importantly, the unstable glucagon formulations will not meet the regulatory requirements to be approved for use in a bionic pancreas. This Phase IIa study will test the effectiveness of the stable glucagon analogue dasiglucagon in the dual-hormone bionic pancreas, comparing it with the unstable glucagon formulation that we have used in all of our previous studies. Demonstrating the effectiveness of a stable glucagon formulation or analogue, such as dasiglucagon, is an essential step towards making a dual-hormone bionic pancreas available to patients."

Adam Steensberg, Senior Vice President, Chief Medical & Development Officer, Zealand: "We are happy to have initiated our fourth Phase II trial this year, showing significant progress in our clinical pipeline of medicines that we fully own and develop ourselves. This is the first trial evaluating Zealand's glucagon analogue, dasiglucagon, in the clinic for use in the dual-hormone artificial pancreas, under development by Beta Bionics and Boston University. Such a system has the ultimate potential to offer people with diabetes on insulin therapy more efficacious, safer and easier blood sugar control."

Zealand entered into a collaboration with Beta Bionics, a Boston-based company, earlier this year. Beta Bionics is developing a dual-hormone artificial (bionic) pancreas system based on advanced technology that was conceived and refined at Boston University and has been undergoing clinical trials for nearly 10 years at the Massachusetts General Hospital and, more recently, Stanford University, the University of North Carolina and the University of Massachusetts. The technology is being integrated at Beta Bionics into a pocket-sized wearable medical device called the iLet TM .

The Phase IIa trials The aim of the Phase IIa clinical trial with Beta Bionics is to assess, for the first time, the safety, efficacy and tolerability of dasiglucagon as part of the Beta Bionics dual-hormone artificial (bionic) pancreas system in adult patients with type 1 diabetes, compared to a recombinant market glucagon. In collaboration with Beta Bionics and Boston University, the trial is conducted at the Massachusetts General Hospital Diabetes Research Center in Boston, MA, USA, with MD Steven J. Russell as Principal Investigator.

Earlier this month, Zealand initiated another Phase IIa trial with the aim of assessing PK and PD responses after administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes. The first patients have been dosed.

The Phase IIa trials are designed to provide the foundation for longer clinical trials with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system. Results from both trials are expected in H1 2017.

For further information on the Phase IIa trials, see: ClinicalTrials.gov Identifier: NCT02916251 ClinicalTrials.gov Identifier: NCT02971228

*****

For further information, please contact

Adam Steensberg, Senior Vice President, Chief Medical and Development Officer Tel.: +45 50 60 36 01 , e-mail: ast@zealandpharma.com

Mats Blom, Senior Vice President, Chief Financial Officer Tel: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates that primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia ® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus ® ) and is approved as Soliqua(TM) 100/33 in the United States, and in Europe a CHMP positive opinion recommendation was given in November (Suliqua(TM) is the brand name in Europe). 

Zealand's proprietary pipeline includes: dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (phase II); glepaglutide* (ZP1848) for short bowel syndrome (phase II); dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in phase II); and other earlier-stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN).

1 Dasiglucagon is a proposed International Nonproprietary Name (pINN)

[2] Russel et al. "Outpatient glycemic control with a bionic pancreas in Type 1 diabetes", New England Journal of Medicine (2014) 

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...c63b1e444f

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 0

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 467

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 48

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 51

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 244

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

EDF Renewables Partners with OPPD for Sustainable Energy Growth

Updated Category News Views 184

EDF Renewables and Omaha Public Power District Join Forces EDF Renewables North America has announced a significant partnership with Omaha Public Power District (OPPD) to enhance the future of renewable energy. Their collaboration centers around the Milligan 1 Wind project, contributing to a larger initiative aimed at delivering cleaner, reliable energy to communities...

Continue Reading
Seaport Therapeutics Welcomes Lauren White as CFO in Growth Strategy

Updated Category News Views 128

Seaport Therapeutics Appoints Lauren White as Chief Financial Officer Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical firm focused on developing innovative neuropsychiatric therapies, recently announced an important leadership change, naming Lauren White as their new Chief Financial Officer. With an impressive track record in biotech financial...

Continue Reading
Lyte Fiber Secures $58 Million to Enhance Broadband Access

Updated Category News Views 461

Lyte Fiber Secures Funding to Expand Broadband Connectivity Lyte Fiber, LLC, based in Houston, has been awarded nearly $58 million through the State’s Bringing Online Opportunities to Texas (BOOT) II Program. This significant funding initiative aims to connect more than 6,750 underserved homes and businesses, thereby supporting the goal of widening broadband access in...

Continue Reading
Chipotle Faces Challenges as Young Consumers Turn to Home Cooking

Updated Category News Views 233

Understanding Current Dining Trends and Chipotle's Position As inflation continues to affect the retail and restaurant sectors, many dining establishments are feeling the pinch, particularly as lower-income consumers scale back on discretionary spending. Chipotle Mexican Grill Inc. (NYSE: CMG) recently faced significant losses in its stock value, dropping 19% in a single...

Continue Reading
Leadership Changes Propel zerohash for Future Growth

Updated Category News Views 288

Leadership Appointments at Zerohash New York-based zerohash has made significant strides in the crypto and stablecoin sector by welcoming Aaron Karczmer and Danny Rosenthal to its Boards of Directors. Their wealth of experience in payments and regulatory frameworks will be instrumental as the company navigates its next growth phase. Bringing Expertise to the Board Aaron...

Continue Reading